Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Oncology and Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-15
DOI
10.1007/s40487-021-00182-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
- (2021) Stephen V. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis
- (2021) Zhicheng Niu et al. Annals of Translational Medicine
- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
- (2020) A.S. Mansfield et al. ANNALS OF ONCOLOGY
- Immunotherapeutic approaches for small-cell lung cancer
- (2020) Wade T. Iams et al. Nature Reviews Clinical Oncology
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer
- (2020) Venu Madhav Konala et al. ONCOLOGY
- Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
- (2020) Francesco Facchinetti et al. Cancers
- Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
- (2020) Ting Zhou et al. JAMA Network Open
- Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
- (2020) Hsiao-Ling Chen et al. Cancers
- LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
- (2019) T K Owonikoko et al. ANNALS OF ONCOLOGY
- 1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
- (2019) M Reck et al. ANNALS OF ONCOLOGY
- LBA89PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
- (2019) L Paz-Ares et al. ANNALS OF ONCOLOGY
- MO3-9-5Subgroup Analysis of Japanese Patients in a Phase I/III Study of Atezolizumab in ES-SCLC (IMpower133)
- (2019) Yosuke Kawashima et al. ANNALS OF ONCOLOGY
- LBA15Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
- (2019) M Nishio et al. ANNALS OF ONCOLOGY
- LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
- (2019) M Özgüroğlu et al. ANNALS OF ONCOLOGY
- PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
- (2019) L. Paz-Ares et al. Journal of Thoracic Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- 49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
- (2018) R Califano et al. ANNALS OF ONCOLOGY
- LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
- (2018) T S K Mok et al. ANNALS OF ONCOLOGY
- A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)
- (2016) L. Horn et al. ANNALS OF ONCOLOGY
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) M. Fruh et al. ANNALS OF ONCOLOGY
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
- (2012) Antonio Rossi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Small-cell lung cancer
- (2011) Jan P van Meerbeeck et al. LANCET
- Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
- (2010) Lorraine C. Pelosof et al. MAYO CLINIC PROCEEDINGS
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Bronchopulmonary neuroendocrine tumors
- (2008) Bjorn I. Gustafsson et al. CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started